PAIN
Volume 149, Issue 2 , Pages 254-262 , May 2010

Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice

  • Phuong N. Quang

      Affiliations

    • UCSF School of Dentistry Oral and Craniofacial Sciences Graduate Program, USA
    • ,
  • Brian L. Schmidt

      Affiliations

    • UCSF Helen Diller Family Comprehensive Cancer Center, USA
    • Department of Oral and Maxillofacial Surgery, USA
    • Corresponding Author InformationCorresponding author. Address: UCSF Department of Oral and Maxillofacial Surgery, Box 0440, 521 Parnassus Ave., Clinic Sci C-525, University of California, San Francisco, CA 94143-0440, USA. Tel.: +1 415 502 3297.

Received 23 October 2009 ,Revised 10 January 2010 ,Accepted 5 February 2010.

References 

  1. Ahmed SI, Thompson J, Coulson JM, Woll PJ. Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol. 2000;22:422–431
  2. Alanen K, Deng DX, Chakrabarti S. Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology. 2000;36:161–167
  3. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–732
  4. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer. 2001;85:1759–1763
  5. Awano S, Dawson LA, Hunter AR, Turner AJ, Usmani BA. Endothelin system in oral squamous carcinoma cells: specific siRNA targeting of ECE-1 blocks cell proliferation. Int J Cancer. 2006;118:1645–1652
  6. Balonov K, Khodorova A, Strichartz GR. Tactile allodynia initiated by local subcutaneous endothelin-1 is prolonged by activation of TRPV-1 receptors. Exp Biol Med (Maywood). 2006;231:1165–1170
  7. Bertelli A, Clerico A, Chicca A, Giovannini L, Gorio A, Romano MA. Role of endothelin-1 in carrageenin-induced inflammation. Int J Tissue React. 1992;14:225–230
  8. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schafer M, Loeffler JP, et al. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest. 1997;100:142–148
  9. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol. 2002;20:2171–2180
  10. Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symp Manage. 2009;38:683–690
  11. Chaplin JM, Morton RP. A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck. 1999;21:531–537
  12. Chen SC, Lin CY, Chen YH, Fang HY, Cheng CY, Chang CW, et al. Aberrant promoter methylation of EDNRB in lung cancer in Taiwan. Oncol Rep. 2006;15:167–172
  13. Chichorro JG, Zampronio AR, Rae GA. Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain. Exp Biol Med (Maywood). 2006;231:1136–1140
  14. Connelly ST, Macabeo-Ong M, Dekker N, Jordan RC, Schmidt BL. Increased nitric oxide levels and iNOS over-expression in oral squamous cell carcinoma. Oral Oncol. 2005;41:261–267
  15. da Cunha JM, Rae GA, Ferreira SH, Cunha Fde Q. Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. Eur J Pharmacol. 2004;501:87–94
  16. Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens. 1990;8:811–817
  17. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med. 2001;2:24–27
  18. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport. 1998;9:2279–2283
  19. De-Melo JD, Tonussi CR, D’Orleans-Juste P, Rae GA. Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain. 1998;77:261–269
  20. Denning GM, Ackermann LW, Barna TJ, Armstrong JG, Stoll LL, Weintraub NL, et al. Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. Peptides. 2008;29:83–92
  21. Ferreira SH, Romitelli M, de Nucci G. Endothelin-1 participation in overt and inflammatory pain. J Cardiovasc Pharmacol. 1989;13:S220–222
  22. Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001;182:19S–26S
  23. Fujioka D, Nakamura S, Yoshino H, Shinohara H, Shiba H, Mizuno N, et al. Expression of endothelins and their receptors in cells from human periodontal tissues. J Periodontal Res. 2003;38:269–275
  24. Fujita M, Andoh T, Saiki I, Kuraishi Y. Involvement of endothelin and ET(A) endothelin receptor in mechanical allodynia in mice given orthotopic melanoma inoculation. J Pharmacol Sci. 2008;106:257–263
  25. Giaid A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yanagisawa M, et al. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci USA. 1989;86:7634–7638
  26. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci. 2001;21:5358–5366
  27. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003;88:163–166
  28. Hans G, Deseure K, Robert D, De Hert S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci Lett. 2007;418:117–121
  29. Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW, Lui WY. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. Oncol Rep. 2006;15:507–511
  30. Hybbinette S, Bostrom M, Lindberg K. Enzymatic dissociation of keratinocytes from human skin biopsies for in vitro cell propagation. Exp Dermatol. 1999;8:30–38
  31. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863–2867
  32. Khodorova A, Fareed MU, Gokin A, Strichartz GR, Davar G. Local injection of a selective endothelin-B receptor agonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner. J Neurosci. 2002;22:7788–7796
  33. Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, Mazurkiewicz JE, et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med. 2003;9:1055–1061
  34. Kikuchi K, Nakagawa H, Kadono T, Etoh T, Byers HR, Mihm MC, et al. Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun. 1996;219:734–739
  35. Kloog Y, Sokolovsky M. Similarities in mode and sites of action of sarafotoxins and endothelins. Trends Pharmacol Sci. 1989;10:212–214
  36. MacCumber MW, Ross CA, Snyder SH. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci USA. 1990;87:2359–2363
  37. Machelska H, Stein C. Pain control by immune-derived opioids. Clin Exp Pharmacol Physiol. 2000;27:533–536
  38. Melzig MF, Nylander I, Vlaskovska M, Terenius L. Beta-endorphin stimulates proliferation of small cell lung carcinoma cells in vitro via nonopioid binding sites. Exp Cell Res. 1995;219:471–476
  39. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18
  40. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24:425–432
  41. Nagahama M, Funasaka Y, Fernandez-Frez ML, Ohashi A, Chakraborty AK, Ueda M, et al. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol. 1998;138:981–985
  42. Namer B, Hilliges M, Orstavik K, Schmidt R, Weidner C, Torebjork E, et al. Endothelin 1 activates and sensitizes human C-nociceptors. Pain. 2008;137:41–49
  43. Nelson JB, Carducci MA. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int. 2000;85:45–48
  44. Ness TJ. Pharmacology of peripheral analgesia. Pain Pract. 2001;1:243–254
  45. Obara I, Przewlocki R, Przewlocka B. Local peripheral effects of mu-opioid receptor agonists in neuropathic pain in rats. Neurosci Lett. 2004;360:85–89
  46. Omar RA, el Tabbakh GH. Immunoreactive beta-endorphin in ovarian sex cord-stromal tumors. Arch Pathol Lab Med. 1987;111:436–439
  47. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004;32:D497–D501
  48. Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience. 2004;126:1043–1052
  49. Pickering V, Jay Gupta R, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain. 2008;12:293–300
  50. Pickering V, Jordan RC, Schmidt BL. Elevated salivary endothelin levels in oral cancer patients – a pilot study. Oral Oncol. 2007;43:37–41
  51. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci. 2001;21:999–1006
  52. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695–1700
  53. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schafer M, et al. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology. 2001;95:500–508
  54. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325–415
  55. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, Mantyh PW. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer. 2003;104:550–558
  56. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732–735
  57. Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, et al. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest. 1994;93:2258–2262
  58. Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, et al. Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain. 2007;11:406–414
  59. Schmidt WK. Alvimopan∗ (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001;182:27S–38S
  60. Shedd DP, Carl A, Shedd C. Problems of terminal head and neck cancer patients. Head Neck Surg. 1980;2:476–482
  61. Shraga-Levine Z, Sokolovsky M. Functional coupling of G proteins to endothelin receptors is ligand and receptor subtype specific. Cell Mol Neurobiol. 2000;20:305–317
  62. Stein C, Hassan AH, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effect of endogenous opioid peptides. Lancet. 1993;342:321–324
  63. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, et al. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci. 2001;21:9355–9366
  64. Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240:728–734[Discussion 734–725]
  65. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, et al. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res. 2003;9:4125–4131
  66. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
  67. Yohn JJ, Smith C, Stevens T, Morelli JG, Shurnas LR, Walchak SJ, et al. Autoregulation of endothelin-1 secretion by cultured human keratinocytes via the endothelin B receptor. Biochim Biophys Acta. 1994;1224:454–458
  68. Yuan CS. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects. J Support Oncol. 2004;2:111–117[Discussion 119–122]
  69. Yuyama H, Koakutsu A, Fujiyasu N, Tanahashi M, Fujimori A, Sato S, et al. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol. 2004;492:177–182

PII: S0304-3959(10)00084-9

doi: 10.1016/j.pain.2010.02.009

PAIN
Volume 149, Issue 2 , Pages 254-262 , May 2010

Article Tools

* Image Usage & Resolution